<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23793762</identifier>
<setSpec>1576-8260</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Domínguez-Escrig, J</dc:author>
<dc:author>Casanova-Casas, I</dc:author>
<dc:author>Fernández-Serra, A</dc:author>
<dc:author>Ramírez Backhaus, M</dc:author>
<dc:author>Casanova Ramón-Borja, J</dc:author>
<dc:author>López-Guerrero, J A</dc:author>
<dc:author>Rubio-Briones, J</dc:author>
<dc:author>Gómez-Ferrer, A</dc:author>
<dc:author>Collado Sierra, A</dc:author>
<dc:description xml:lang="en">The great number of biomarkers basic research is presenting in different clinical scenarios of prostate cancer demands the scientific community rigor in their molecular and clinical development for the selection of those which could supply diagnostic and prognostic information for the established nomograms of clinical-pathological factors. Prostate cancer, due to its prevalence and heterogeneity, needs a more directed diagnosis, characterization of malignant potential and monitoring of its multiple therapies. In this review article we try to go over the recent incorporation of new serum and urine markers in the clinical management of this tumor, emphasizing those with greater clinical development.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Jun </dc:date>
<dc:title xml:lang="es">Diagnóstico no invasivo del cáncer de próstata; marcadores séricos y en orina.</dc:title>
<dc:title xml:lang="en">[Non-invasive diagnosis of prostate cancer: serum and urine markers].</dc:title>
<dc:publisher>Archivos espanoles de urologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
